CASI Pharmaceuticals, Inc.
CASIF evidence brief
What we can confirm
- Market Cap:
- $2.7M
What it means
What to watch
Prepared research question
What matters most for CASIF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CASIF
CASI Pharmaceuticals is a biopharmaceutical company pivoting from China-focused operations to concentrate on developing CID-103 for organ transplant rejection and autoimmune diseases, after selling its Chinese subsidiaries and facing significant financial challenges.
Key risk: Going concern risk from losses
Market Cap
$2.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 5 clinical trials for CASI Pharmaceuticals, Inc..
CASI Pharmaceuticals is a biopharmaceutical company pivoting from China-focused operations to concentrate on developing CID-103 for organ transplant rejection and autoimmune diseases, after selling its Chinese subsidiaries and facing significant financial challenges.
- CASI is pivoting to focus on CID-103 for organ transplant rejection and autoimmune diseases after selling its Chinese subsidiaries [sec · filed 2026-05-15].
- The company had an accumulated deficit of $748.1 million and a net loss of $48.1 million for the year ended December 31, 2025 [sec · filed 2026-05-15].
- Cash of $5.6M and shareholders' equity of -$37.3M as of December 31, 2025 [latest reported financials (from SEC structured data) as of 2025-12-31].
- CID-103 has FDA IND clearance for renal allograft antibody mediated rejection and an NMPA-approved Phase 1/2 trial in China [sec · filed 2026-05-15].
- A preliminary non-binding proposal was received in January 2026 from Chairman Dr. Wei-Wu He to acquire outstanding shares at $1.15 per share [sec · filed 2026-05-15].
What works
- CID-103 has entered clinical trials in the U.S. and China for renal allograft antibody mediated rejection, with FDA clearance in August 2025 and NMPA approval in January 2026 [sec · filed 2026-05-15].
- The company retains rights to CID-103 (outside Asia), EVOMELA, FOLOTYN, CNCT19, and CB-5339 after the China subsidiary sale, preserving a pipeline of late-stage assets [sec · filed 2026-05-15].
- The strategic pivot to organ transplant rejection and autoimmune diseases represents a focused approach to a large unmet medical need [sec · filed 2026-05-15].
What to weigh
- CASI has never generated sufficient revenue to cover expenses and has incurred a net loss of $48.1 million in 2025, with an accumulated deficit of $748.1 million [sec · filed 2026-05-15].
- Cash of only $5.6M and negative shareholders' equity indicate severe funding constraints that raise substantial doubt about going concern [sec · filed 2026-05-15].
- The company relies on a single source for supply of both EVOMELA and FOLOTYN, exposing it to supply chain risks [sec · filed 2026-05-15].
- The board has received a take-private proposal at $1.15 per share, adding potential takeover-related distractions and execution risks [sec · filed 2026-05-15].
From the filings
Quoted directly from source documents.
CASI's recurring losses raise substantial doubt about its ability to continue as a going concern.
“Our Recurring Operating Losses have Raised Substantial Doubt Regarding Our Ability to Continue as a Going Concern. Our recurring operating losses raise substantial doubt about our ability to continue as a going concern. Since our inception in 1991, we have incurred significant losses from operations and, as of December 31, 2025, had incurred an accumulated deficit of $748.1 million.”
SEC filings · May 15, 2026
CID-103 received FDA IND clearance for renal allograft AMR in August 2025.
“In August 2025, we announced FDA clearance of an IND application for CID-103 in adults with active and chronic active renal allograft antibody mediated rejection (AMR).”
SEC filings · May 15, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk from losses — Substantial doubt about ability to continue due to $748.1M accumulated deficit and negative equity. [sec · filed 2026-05-15]
- Very low cash runway — Cash of $5.6M as of Dec 31, 2025, insufficient to fund operations for more than a few months. [latest]
- Single-source supply risk — Both approved products EVOMELA and FOLOTYN rely on a single source supplier. [sec · filed 2026-05-15]
- Takeover proposal uncertainty — Dr. He's non-binding proposal introduces strategic uncertainty and may distract from operations. [sec · filed 2026-05-15]
What to watch
- Outcome of the take-private proposal from Dr. Wei-Wu He, with no decision as of the filing date [sec · filed 2026-05-15].
- Clinical progress of CID-103 in the ongoing U.S. and China Phase 1/2 trials for renal allograft AMR [sec · filed 2026-05-15].
- Funding or partnering updates to address the cash deficit and liquidity needs, given $5.6M cash position as of 2025-12-31 [latest].
- Investor updates on the commercialization status of EVOMELA (approved) and FOLOTYN (approved) in China and Japan [sec · filed 2026-05-15].
Sources: SEC filings · Generated September 11, 2026 · How we verify sources →
Run CASI Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CASI Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$25
| Holder | Shares | Value |
|---|---|---|
| simplex trading, llc | 228 | $25 |
Short Interest
as of May 20, 2026- % of float
- 0.5%
- Days to cover
- 2.4
- Shares short
- 90,948
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CASIF short interestFrequently asked questions
What is the AI investment thesis for CASI Pharmaceuticals, Inc.?
CASI Pharmaceuticals is a biopharmaceutical company pivoting from China-focused operations to concentrate on developing CID-103 for organ transplant rejection and autoimmune diseases, after selling its Chinese subsidiaries and facing significant financial challenges.
Where is CASI Pharmaceuticals, Inc. headquartered?
CASI Pharmaceuticals, Inc. (CASIF) is headquartered in Beijing, China.
What therapeutic areas does CASI Pharmaceuticals, Inc. focus on?
CASI Pharmaceuticals, Inc. develops therapies across Oncology, Ophthalmology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.